Interferon induction regimen for chronic hepatitis C genotype 4 in Egyptian children

Journal of Pediatric Infectious Diseases

Volumn 5, Issue 3, 2010, Pages 233-241

  El Araby, Hanaa A ^a   Sira, Mostafa M ^a   Behairy, Behairy E ^a   El Refaie, Amany O ^b   Ghoneim, Enas M ^b  

^a MENOUFIA UNIVERSITY   (Egypt)

^b MENOUFIA UNIVERSITY   (Egypt)

Author keywords

Chronic hepatitis C; interferon; liver disease; ribavirin

Indexed keywords

ALPHA2 INTERFERON; RIBAVIRIN;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EGYPT; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; LEUKOPENIA; MALE; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; VIREMIA; VIROLOGY; VIRUS LOAD;

EID: 78650388883     PISSN: 13057707     EISSN: None     Source Type: Journal    
DOI: 10.3233/JPI-2010-0249     Document Type: Article

References (25)

1. D.P. Webster, P. Klenerman, J. Collier and K.J. Jeffery, Devel-opment of novel treatments for hepatitis C, Lancet Infect Dis 9(2009), 108-117.
2. M.S. El-Raziky, M. El-Hawary, G. Esmat et al., Prevalence and risk factors of asymptomatic hepatitis C virus infection in Egyptian children, World J Gastroenterol 13 (2007), 1828-1832.
3. S. Davison and E.H. Boxall, Infective disorders of the liver, in: Diseases oftheLiver andBiliary System in Children, (3rd ed.), D. Kelly, ed., Oxford: Wiley-Blackwell, 2008, pp. 129-168.
4. M.P. Busch, S.A. Glynn, S.L. Stramer et al., A new strate-gy for estimating risks of transfusion-transmitted viral infec-tions based on rates of detection of recently infected donors, Transfusion 45 (2005), 254-264.
5. M. Irshad and S. Peter, Spectrum of viral hepatitis in tha-lassemic children receiving multiple blood transfusions, Indian J Gastroenterol 21 (2002), 183-184.
6. B. Fischler, Hepatitis C virus infection, Semin Fetal Neonatal Med 12 (2007), 168-173.
7. C. Camarero, N. Ramos, A. Moreno, A. Asensio, M.L. Mateos and B. Roldan, Hepatitis C virus infection acquired in childhood, Eur J Pediatr 167 (2008), 219-224.
8. R. Giacchino, F. Bortolotti, G. Indolfietal., Antiviral treatment of hepatitis C in Italian children, Dig Liver Dis 41 (2009), A7-A8.
9. J. Neyts, Selective inhibitors of hepatitis C virus replication, Antiviral Res 71 (2006), 363-371.
10. M. Cornberg, J. Hadem, E. Herrmann et al., Treatment with daily consensus interferon (CIFN) plus ribavirin in nonresponder patients with chronic hepatitis C: a randomized open-label pilot study, J Hepatol 44 (2006), 291-301.
11. F. Poordad, K.R. Reddy and P. Martin, Rapid virologic response: a new milestone in the management of chronic hepatitis C, Clin Infect Dis 46 (2008), 78-84.
12. K. Ishak, A. Baptista, L. Bianchi et al., Histological grading and staging of chronic hepatitis, J Hepatol 22 (1995), 696-699.
13. J. Salmerón, J. Casado, P.M. Rueda et al., Quasispecies as predictive factor of rapid, early and sustained virological responses in chronic hepatitis C, genotype 1, treated with peginterferon-ribavirin, J Clin Virol 41 (2008), 264-249.
14. K.R. Reddy, D.R. Nelson and S. Zeuzem, Ribavirin: current role in the optimal clinical management of chronic hepatitis C, J Hepatol 50 (2009), 402-411.
15. G. Esmat, M. Metwally, K.R.Zalataetal., Evaluationof serum biomarkers of fibrosis and injury in Egyptian patients with chronic hepatitis C, J Hepatol 46 (2007), 620-627.
16. M. Figlerowicz, W. Sluzewski, A. Kowala-Piaskowska and I. Mozer-Lisewska, Interferon alpha and ribavirin in the treatment of children with chronic hepatitis C, Eur J Pediatr 163 (2004), 265-267.
17. R.P. González-Peralta, D.A. Kelly, B. Haber et al., Interfer-on alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharma-cokinetics, Hepatology 42 (2005), 1010-1018.
18. S. Wirth, H. Pieper-Boustani, T. Lang et al., Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C, Hepatology 41 (2005), 1013-1018.
19. M.P. Manns, J.G. Mc Hutchison, S.C. Gordon et al., Peginter-feron alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet 358 (2001), 958-965.
20. S.M. Kamal, Hepatitis C genotype 4therapy: increasing op-tions and improving outcomes, Liver Int 29(Suppl 1) (2009), 39-48.
21. R. Varghese, J. Al-Khaldi, H. Asker, A.A. Fadili, J. Al Ali and F.A. Hassan, Treatment of chronic hepatitis C genotype 4 with peginterferon alpha-2a plus ribavirin, Hepatogastroenterology 56 (2009), 218-222.
22. M.W. Russo and M.W. Fried, Guidelines for stopping therapy in chronic hepatitis C, Curr Gastroenterol Rep 6 (2004), 17-21.
23. A. Crax̀, Early virologic response with pegylated interferons, Dig Liver Dis 36(Suppl 3) (2004), S340-S343.
24. V. de Lédinghen, P. Trimoulet, M. Winnock et al., Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone forthe treatment of patients with chronic hepatitis C, J Hepatol 36 (2002), 672-680.
25. M.R. Narkewicz, R. Cabrera and R.P. González-Peralta, The "C" of viral hepatitis in children, Semin Liver Dis 27 (2007), 295-311.